NVAX vs. BCRX, PROK, PRME, ALLO, VALN, HLVX, CABA, EXAI, FATE, and ALEC
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include BioCryst Pharmaceuticals (BCRX), ProKidney (PROK), Prime Medicine (PRME), Allogene Therapeutics (ALLO), Valneva (VALN), HilleVax (HLVX), Cabaletta Bio (CABA), Exscientia (EXAI), Fate Therapeutics (FATE), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Novavax (NASDAQ:NVAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.
In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Novavax. MarketBeat recorded 5 mentions for BioCryst Pharmaceuticals and 4 mentions for Novavax. Novavax's average media sentiment score of 0.20 beat BioCryst Pharmaceuticals' score of -0.02 indicating that Novavax is being referred to more favorably in the media.
Novavax has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.
BioCryst Pharmaceuticals has lower revenue, but higher earnings than Novavax. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
53.0% of Novavax shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 0.9% of Novavax shares are held by insiders. Comparatively, 4.4% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Novavax has a net margin of -55.41% compared to BioCryst Pharmaceuticals' net margin of -68.36%.
Novavax currently has a consensus target price of $17.00, suggesting a potential upside of 309.64%. BioCryst Pharmaceuticals has a consensus target price of $13.83, suggesting a potential upside of 228.58%. Given Novavax's higher possible upside, research analysts clearly believe Novavax is more favorable than BioCryst Pharmaceuticals.
Novavax received 367 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 74.29% of users gave Novavax an outperform vote while only 66.29% of users gave BioCryst Pharmaceuticals an outperform vote.
Summary
Novavax and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
